Next Day Disclosure Return
Filed with HKEX · Stock code 9966 · · 5 pages · English
Earlier from Alphamab Oncology
- Voluntary announcement - IND approval by the FDA for a phase I clinical study of JSKN021
- Supplementary announcement on discloseable transaction
- Voluntary announcement - first patient dosed in phase III clinical study of JSKN033 monotherapy for the treatment of cervical cancer
- Grant of award shares under the restricted share award scheme
- Voluntary announcement - latest research updates of JSKN003 presented at the 2026 ESMO congress
Later from Alphamab Oncology
All Alphamab Oncology news releasesFollow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology